Recent Updates
Recently added Catalysts
Specialist biotech fund · SEC 13F

VR Adviser 13F Holdings (Q3 2026)

According to its SEC 13F filed on Nov 16, 2026, VR Adviser reported 32 long positions worth $2.06B as of Sep 30, 2026. ORKA is 16.8% of the portfolio and the top 10 holdings are 71%. Against Q2 2026 it opened 4 new positions, added to 6, trimmed 5 and exited 4. 9 holdings have a dated FDA decision or data readout in the next 90 days, and 6 more expect one in a stated window such as "H2 2026".

Data as of Sep 30, 2026SEC 13F filed Nov 16, 2026Next filing (Q4 2026) due Feb 16, 2027Value as filed; options at underlying sharesLong positions only
Market Value$ 2.06 B13F value, as filed
QoQ Changes-37.59 %13F value vs the previous quarter
Holdings34 32 stocks · 0 option positions
PeriodQ3 202613F reporting quarter
Holdings in Top 20 % top 10: 71% of the portfolio
Activity vs Q2 20264 new6 added · 5 trimmed · 4 exits
Catalysts ahead9dated in 90 days · +6 in a stated window

Catalysts ahead in this portfolio

Dated FDA decisions and data readouts for its holdings in the next 90 days, with our probability of approval

Nov 18, 2026KRSAPre-clinical data presentation: KRSA-028PoA 3%
Nov 19, 2026ANLPhase 1 data presentation: AN4035PoA 8%

7 more with a subscription

What changed vs Q2 2026

KRSAKorsana Biosciences, Inc.$146M
ADRXADARx Pharmaceuticals, Inc.$32M

Full lists with a subscription

Portfolio over time

13F value by quarter, Q1 2021 to Q3 2026

Q1 2021: $922MQ3 2026: $2.06B

By company stage (share of value)

Clinical 81%Other 10%Commercial 9%

Holdings

Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.

Showing 6 Stocks Out Of 34. Click On The Tickers For More Details
Stock Company Name Shares Held Market Value % of Portfolio QoQ Change Position Change Also Held By Stage Next Catalyst
INM
INM
INMED PHARMACEUTICALS INC
133.38 K
181.39 K
0
Added +308%
Clinical
None in 90 days
VRDN
VRDN
VIRIDIAN THERAPEUTICS INC
3.26 M
67.08 M
3.3
Unchanged
Commercial
Expected Q4 2026
IND Submission
SRZN
SRZN
SURROZEN INC
632.93 K
20.37 M
1
Unchanged
Clinical
None in 90 days
MAZE
MAZE
MAZE THERAPEUTICS INC
1.55 M
42.01 M
2
Trimmed -4%
Clinical
None in 90 days
KRSA
KRSA
KORSANA BIOSCIENCES INC
4.55 M
145.59 M
7.1
New
—
Nov 18, 2026
Pre-clinical data presentation
ENTX
ENTX
ENTERA BIO LTD
5.11 M
14.86 M
0.7
New
Clinical
None in 90 days

Top 20 Holdings

Size = share of the portfolio. Option positions show CALL or PUT.

Who else owns these stocks?

All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.

Open All Stock Holdings ›

Questions about VR Adviser's 13F

What does VR Adviser own?

32 stocks worth $2.06B at Sep 30, 2026, as reported in its 13F, led by ORKA (16.8% of the portfolio). The full list is in the Holdings table above.

What did it buy and sell last quarter?

Against Q2 2026: 4 new positions, 6 increases, 5 reductions and 4 full exits, from its 13F filings.

How current is this data?

13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q4 2026) is due Feb 16, 2027.

Why are some positions labelled CALL or PUT?

Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.

Source: SEC EDGAR Form 13F-HR filed by VR Adviser, LLC, accession 0001615982-26-000019, filed Nov 16, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.